BPC-157 is a synthetic 15-amino-acid peptide used in experimental research examining peptide-mediated cellular signalling, endothelial pathways, nitric-oxide-associated mechanisms, cellular stress responses, inflammatory signalling and gastrointestinal cell models. This article summarises published laboratory and preclinical literature for scientific reference and does not provide instructions for human or veterinary use.
BPC-157 is a synthetic pentadecapeptide. For structural context, see our guide on what is a pentadecapeptide.
Quick reference
| Property | Value |
|---|---|
| Compound class | Pentadecapeptide (15 amino acids) |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Molecular formula | C₆₂H₉₈N₁₆O₂₂ |
| Molecular weight | 1419.53 g/mol |
| CAS number | 137525-51-0 |
| Origin | Synthetic fragment of human gastric juice protein BPC |
| Form | Lyophilised white powder |
| Storage | 2–8°C refrigerated; −20°C for long-term lyophilised storage; protect from light and moisture |
Introduction
BPC-157 is a synthetic pentadecapeptide consisting of 15 amino acids. It is based on a sequence identified within a larger gastric protein and is studied as a synthetic research peptide rather than as a naturally occurring isolated 15-amino-acid molecule.
Since its initial characterisation in the 1990s, BPC-157 has been the subject of a large body of published preclinical research. The majority of this evidence comes from animal models and in vitro studies, with no completed phase 3 clinical trials in humans at the time of writing. Despite this, the breadth of preclinical findings — spanning gastrointestinal models, endothelial signalling, angiogenesis and nitric-oxide-associated mechanisms — has made BPC-157 one of the most widely discussed research peptides in the scientific literature.
Mechanism of action
BPC-157’s mechanism of action is not fully characterised at the molecular level, which is common for peptides with pleiotropic effects across multiple tissue systems. Published research has identified several pathways through which the compound appears to exert biological activity in preclinical models.
Nitric oxide system modulation
Published research has identified the nitric oxide (NO) system as a central mediator of BPC-157’s effects. Studies have reported that BPC-157 modulates nitric oxide synthase (NOS) activity in multiple tissue contexts — upregulating NO production in some settings (such as vascular endothelium) and modulating it in others (such as inflammatory contexts). The compound appears to interact with the NO system bidirectionally, which may explain its observed effects across diverse tissue types (Sikiric et al., 2018).
Angiogenesis-associated signalling
Published in vitro and animal studies have examined BPC-157 alongside angiogenesis-associated endpoints, including VEGF/VEGFR2 expression, endothelial-cell behaviour and vessel-formation measurements. These findings describe experimental observations in defined models and do not establish a therapeutic effect in humans.
Growth factor pathway interaction
Preclinical research has reported interactions between BPC-157 and several growth factor signalling pathways relevant to cellular signalling and matrix-associated experimental models, including fibroblast growth factor (FGF), epidermal growth factor (EGF), and transforming growth factor beta (TGF-β). The compound has been reported to upregulate growth hormone receptor expression in some tissue contexts, though the specificity and consistency of these interactions remains an active area of investigation.
FAK-paxillin pathway
More recent published research has identified the focal adhesion kinase (FAK) and paxillin signalling pathway as a potential mediator of BPC-157’s effects on cell migration and tissue remodelling. FAK-paxillin signalling is involved in cell adhesion, migration, and survival — processes examined in experimental wound, matrix-remodelling and connective-tissue models. Studies have reported that BPC-157 promotes FAK-paxillin pathway activation in tendon fibroblasts and other cell types used in musculoskeletal experimental models.
Gastrointestinal cell and tissue models
BPC-157 has been examined in gastric and intestinal experimental systems, including models involving mucosal injury, inflammatory signalling and barrier-associated endpoints. Reported mechanisms in this literature include prostaglandin-associated signalling, nitric-oxide pathways and interactions with dopamine- and serotonin-associated systems.
Published research
BPC-157 has an unusually large preclinical research base for a peptide that has not yet completed phase 3 clinical trials. The majority of published findings come from animal models (primarily rodent) and in vitro cell culture studies. This section summarises key research areas. Researchers should note that preclinical findings do not necessarily translate to human outcomes and should consult the cited sources directly for full study details.
Musculoskeletal experimental models
A substantial part of the BPC-157 literature uses musculoskeletal and connective-tissue models. Published rodent studies have examined transected Achilles tendon, medial collateral ligament and rotator-cuff models, with reported changes in collagen organisation, fibroblast activity, angiogenesis-associated signalling and other tissue-response parameters.
Research published in the Journal of Orthopaedic Research and Journal of Applied Physiology has also examined exposure-response relationships and time-course measurements in controlled musculoskeletal models.
Experimental wound models
Published research has examined BPC-157 in several animal wound models, including incisional, burn and diabetic-wound systems. Reported experimental endpoints have included granulation-tissue formation, epithelialisation, angiogenesis-associated signalling and wound-closure measurements relative to control groups.
Gastrointestinal experimental models
Consistent with its origin as a gastric juice protein fragment, BPC-157 has been studied in numerous gastrointestinal damage models. Published research reports cytoprotective effects in ethanol-induced gastric lesions, NSAID-induced intestinal damage, inflammatory bowel disease models, and anastomotic healing models. Sikiric and colleagues have published extensively in this area, with studies appearing in journals including Life Sciences, Journal of Physiology and Pharmacology, and Current Medicinal Chemistry (Sikiric et al., 2018; Sikiric et al., 2014).
Vascular research
Published animal studies have examined BPC-157 in vascular experimental systems, including measurements of vessel formation, nitric-oxide-associated signalling, blood-flow-related parameters and responses in arterial or venous models. These are model-specific observations rather than evidence of a clinical vascular benefit.
Neurological experimental models
A smaller body of preclinical literature has examined BPC-157 in neurological models, including traumatic injury, peripheral-nerve and spinal-cord experimental systems. Reported endpoints include nitric-oxide-associated signalling, vascular responses and neural-cell or functional measurements in animals. The evidence remains preclinical.
Limitations of current evidence
It is important to note that the BPC-157 research base, while extensive, is almost entirely preclinical. The compound has not completed phase 3 clinical trials in humans, and the majority of published research comes from a relatively small number of research groups — most notably the group led by Predrag Sikiric at the University of Zagreb. Independent replication of findings by unaffiliated research groups is growing but remains limited compared to the breadth of claims in the published literature. Researchers should interpret findings with this context in mind.
Research use only. This article is provided for laboratory and scientific reference purposes. Trutide research products are supplied strictly for in vitro laboratory research and are not for human or veterinary use, clinical use, self-administration, diagnosis, treatment or prevention of disease.
References
- Sikiric P, Hahm KB, Blagaic AB, et al. Stable gastric pentadecapeptide BPC 157, Robert’s cytoprotection, Selye’s stress coping response, and Szabo’s interaction of stress and non-steroidal anti-inflammatory drugs (NSAIDs). Current Pharmaceutical Design. 2020;26(25):2985-3000.
- Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology. 2016;14(8):857-865.
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Current Pharmaceutical Design. 2014;20(7):1126-1135.
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010
- Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. 2010;28(9):1155-1161.
- Sikiric P, Seiwerth S, Rucman R, et al. Pentadecapeptide BPC 157 and its effects: a review. Journal of Physiology and Pharmacology. 2018;69(3).
Last updated: 15 May 2026